Gress and colleagues from the University of Marburg in Germany published the results of a Phase II trial in the October issue of the Annals of Oncology, the official journal of the European Society for Medical Oncology. They did a prospective multi-center study of 76 patients over a two-year period which offered the adjuvant regimen of gemcitabine in combination with cetuximab (Tarceva) to patients for a 24 week period post-pancreatic cancer surgery.
The authors compared the results of these study subjects with pancreatic cancer to previously reported survival statistics at 18 months of a 35% disease-free survival rate – for gemcitabine alone. Their conclusion was that adding Tarceva to the gemcitabine did NOT improve either disease-free survival or overall survival of those with pancreatic cancer receiving this combination above previously reported gemcitabine-alone results.
Dale O’Brien, MD